ImmunoMet Therapeutics develops therapies targeting metabolic reprogramming in oncology and fibrosis, utilizing its proprietary oxidative phosphorylation inhibitor, IM156. The company aims to improve treatment outcomes for cancer patients by addressing the metabolic vulnerabilities of tumors, particularly in advanced solid tumors like pancreatic cancer.
Funding
$40.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers and fibrotic diseases exhibit metabolic reprogramming, making them resistant to conventional therapies. Current treatments often fail to address the unique metabolic vulnerabilities of these diseases, leading to limited efficacy and poor patient outcomes, especially in advanced solid tumors.
Solution
ImmunoMet Therapeutics is developing small molecule therapies that target cellular metabolism to treat cancer and fibrotic diseases. Their lead compound, lixumistat (IM156), is an orally bioavailable inhibitor of protein complex 1 (PC1), which targets oxidative phosphorylation (OxPhos) to decrease aberrant cell growth and proliferation. By modulating metabolic pathways in tumor and immuno-suppressive cells, ImmunoMet's approach aims to overcome resistance mechanisms and improve long-term survival. Lixumistat has completed Phase 1 studies demonstrating target inhibition and good tolerability, making it the first PC1 inhibitor to reach this stage of development. The company's pipeline focuses on eliminating tumors by targeting resistant cell subpopulations and mitigating myofibroblast formation in fibrosis.
Target Audience
The primary target audience includes patients with advanced solid tumors, particularly pancreatic cancer, and individuals suffering from fibrotic diseases, as well as the clinicians treating these conditions.
Features
- Orally bioavailable small molecule inhibitor of protein complex 1 (PC1)
- Targets oxidative phosphorylation (OxPhos) to disrupt cancer cell metabolism
- Designed to suppress disease progression by modulating metabolic signatures
- Demonstrated target inhibition in Phase 1 clinical trials with once-daily dosing
- Potential to prevent both the initiation and advancement of fibrosis by mitigating myofibroblast formation
- Intended for use in combination with current standard of care therapies